DIAGNOS Enters the Retinal Diagnostics Market With its New 3D Image Analysis Technology
October 27 2022 - 11:29AM
DIAGNOS Inc. (“
DIAGNOS”, the
“
Corporation” or ”we”) (TSX Venture: ADK) (OTCQB:
DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is proud to announce it is entering the
fast-growing retinal diagnostics market, armed with its new 3D
image analysis technology.
DIAGNOS is pushing the boundaries of the
practice with a deep learning-powered technology capable of
diagnosing retinal conditions such as Age-Related Macular
Degeneration, Diabetic Retinopathy, Glaucoma, Macular Edema,
Retinal Cancer, and other retinal and macular diseases. Moreover,
neurological and systemic diseases affecting other parts of the
body can also be identified, including Alzheimer’s disease,
cardiovascular diseases, multiple sclerosis, Parkinson’s disease,
etc.
The multimodal data analysis tools developed by
DIAGNOS take advantage of the most recent advancements in
ophthalmic science. Combining data fetched from retinal images and
optical coherence tomography (OCT) scans, DIAGNOS uses the most
accurate technologies that exist for retinal diagnostics. The
technology is more precise than MRI and ultrasound scanning, it is
non-invasive, and integrates the analysis of 3D cross-sectional
images of the retina”.“The growing interest for advanced retinal
imaging systems by the healthcare sector, the adoption of
healthcare reimbursement policies in multiple regions, and the
evolution of the regulatory environment are some of the factors
that made us take the decision to enter the retinal diagnostics
market”, stated Mr. Andre Larente,
President of DIAGNOS. “Two of our main competitors have
recently received investments of respectively $50M and $26M
following their decision to enter the retinal diagnostics market,
it certainly tells a lot about the potential of this category”.
Technological advancements in diagnostic
methods, rapidly changing healthcare infrastructure, growing
adoption of advanced retinal imaging systems, and favorable
healthcare reimbursement policies contribute to the rapid growth of
this category, as it is expected to become the gold standard of the
future in the successful management of retinal disorders.
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available at
www.DIAGNOS.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450
678-8882, ext. 224Email: alarente@DIAGNOS.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/d943a458-d0b6-43db-8cc4-39482d7f9b85
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024